Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zoom therapy aims to break barriers for deaf individuals seeking mental health help

NCT ID NCT07279363

Symptom relief Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a two-session Zoom-based therapy designed to change beliefs about mental health treatment in Deaf adults who are not currently in care. Researchers will compare those who receive the therapy to a waitlist group to see if it increases treatment-seeking and reduces suicide risk. The trial involves 110 Deaf adults who use American Sign Language and have untreated depression, anxiety, PTSD, insomnia, or alcohol use problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cognitive Behavioral Therapy for Treatment-Seeking (Deaf CBT-TS)
What this could lead to
If it works, this could help Deaf adults feel more comfortable seeking mental health treatment and lower their risk of suicide.
What could go wrong
This is a small, early-stage trial with only 110 participants. The intervention is brief (two sessions), so it may not be enough to create lasting change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * adult (aged 18 years or older) * Self-identify as Deaf or hard of hearing (any degree of hearing loss) * Primary method of communication is American Sign Language * Positive screen for one or more mental health disorders including depression (PHQ-9 \> 10), anxiety (GAD-7 \> 10), posttraumatic stress disorder (PCL-5 \> 31), insomnia (ISI \> 15), or alcohol use disorder (AUDIT \> 16) * No current professional mental health or alcohol specialty treatment (e.g., counseling, psychiatric services) per standardized self-report * Access to video chat technology with internet and webcam. Exclusion criteria: * unable to communicate with the researcher in American Sign Language * current alcohol withdrawal necessitating medical evaluation * current psychiatric impairment necessitating emergency services or inpatient admission (i.e., imminent danger of harm to self or others) * unable to comprehend the nature of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol use disorder (AUD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcohol abuse anxiety anxiety disorder combat disorder depressive disorder insomnia major depressive disorder post-traumatic stress disorder Psychological Well-Being Suicide

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol use disorder (AUD) Anxiety Depression - major depressive disorder Insomnia PTSD - post traumatic stress disorder Suicide ideation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.